Last $0.24 USD
Change Today +0.005 / 2.17%
Volume 7.1K
CAPS On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

capstone therapeutics corp (CAPS) Snapshot

Open
$0.24
Previous Close
$0.23
Day High
$0.24
Day Low
$0.24
52 Week High
09/11/14 - $0.39
52 Week Low
11/7/13 - $0.21
Market Cap
9.6M
Average Volume 10 Days
32.2K
EPS TTM
$-0.10
Shares Outstanding
40.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CAPSTONE THERAPEUTICS CORP (CAPS)

Related News

No related news articles were found.

capstone therapeutics corp (CAPS) Related Businessweek News

No Related Businessweek News Found

capstone therapeutics corp (CAPS) Details

Capstone Therapeutics Corp., a biotechnology company, focuses on developing a pipeline of peptides and other molecules for helping patients with under-served medical conditions. It develops AZX100, a novel synthetic 24-amino acid peptide that has completed Phase 2 study for dermal scarring, and is in pre-clinical studies for Pulmonary Fibrosis and Peridural Fibrosis; and Apo E mimetic peptide molecule AEM-28 and its analogs that play an important role in lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

2 Employees
Last Reported Date: 08/14/14
Founded in 1987

capstone therapeutics corp (CAPS) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $100.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $120.0K
Consultant
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2013.

capstone therapeutics corp (CAPS) Key Developments

Capstone Therapeutics and LipimetiX Development, LLC Announce Phase 1A Results for AEM-28

Capstone Therapeutics and its joint venture affiliate, LipimetiX Development, LLC, announced the completion of dosing and patient follow-up for its investigational AEM-28 (Apo E mimetic peptide) Phase 1a human clinical trial in cholesterol and lipid reduction. The Medical Safety Committee, reviewing all safety-related aspects of the clinical trial, observed an acceptable safety profile. As a first-in-man study, the primary endpoint was safety, yet, biomarker efficacy measurements analyzing pharmacodynamics yielded trends favoring AEM-28 versus placebo in multiple cholesterol and lipid endpoints. The clinical study, performed at a hospital-affiliated clinical research site in Perth, Australia was a Phase 1a randomized, placebo-controlled, double-blinded study testing six escalating single doses of AEM-28. There were six patients (including two placebo and four active) in each of the dosing cohorts for a total of 36 subjects. The patients fasted and were given an industry standard pre-medication regimen prior to IV administration of study drug. Follow up occurred over a fourteen day time frame. The primary objectives were to evaluate safety and tolerability and to determine preliminary pharmacokinetics/pharmacodynamics of AEM-28 in normal healthy volunteers with elevated cholesterol. The Phase 1a study sequenced into a Phase 1b/2a multiple ascending dose study testing the three higher doses from Phase 1a. The Phase 1b/2a study is testing five patients (including one placebo and four active) in each of the dosing cohorts for a total of 15 subjects. Administration of placebo and study drug will occur at three intervals two weeks apart. The patient population, initially targeted for refractory hypercholesterolemics, has been expanded to include normal healthy volunteers with elevated cholesterol and high Body Mass Index in order to facilitate enrollment. All clinical aspects and study objectives are the same as the Phase 1a study.

Capstone Therapeutics Corp. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Capstone Therapeutics Corp. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. The company incurred a net loss attributable to the company stockholders in the second quarter of 2014 of $1.4 million or $0.03 per basic and diluted share compared to a net loss of $1.0 million or $0.02 per basic and diluted share in the second quarter of 2013. Net loss fluctuates primarily from the inclusion of the operating expenses of LipimetiX Development, LLC, which totaled (net of intercompany transactions) $987,000 for the three months ended June 30, 2014, and $584,000 for the three months ended June 30, 2013. Loss from continuing operations before taxes was $1,391,000 against $1,029,000 a year ago. Loss from continuing operations was $1,391,000 against $1,008,000 a year ago. The company incurred a net loss attributable to the company stockholders in the six months ended June 30, 2014 of $2.4 million or $0.06 per basic and diluted share compared to a net loss of $2.0 million or $0.05 per basic and diluted share for the same period in 2013. Net Loss includes the operating expenses of LipimetiX Development, LLC, which totaled (net of intercompany transactions) $1,408,000 for the six months ended June 30, 2014, and $1,415,000 for the six months ended June 30, 2013. Loss from continuing operations before taxes was $2,413,000 against $2,218,000 a year ago. Loss from continuing operations was $2,413,000 against $2,197,000 a year ago.

Capstone Therapeutics Corp., Q2 2014 Earnings Call, Aug 14, 2014

Capstone Therapeutics Corp., Q2 2014 Earnings Call, Aug 14, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CAPS:US $0.24 USD +0.005

CAPS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CAPS.
View Industry Companies
 

Industry Analysis

CAPS

Industry Average

Valuation CAPS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAPSTONE THERAPEUTICS CORP, please visit www.capstonethx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.